Health-related quality of life in survivors of septic shock: 6-month follow-up from the ADRENAL trial

the ADRENAL Trial Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group; Naomi Hammond; Simon R. Finfer; Qiang Li; Colman Taylor; Jeremy Cohen; Yaseen Arabi; Rinaldo Bellomo; Laurent Billot; Meg Harward; Chris Joyce; Colin McArthur; John Myburgh; Anders Perner; Dorrilyn Rajbhandari; Andrew Rhodes; Kelly Thompson; Steve Webb; Balasubramanian Venkatesh

doi:10.1007/s00134-020-06169-1

Health-related quality of life in survivors of septic shock: 6-month follow-up from the ADRENAL trial

the ADRENAL Trial Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Naomi Hammond, Simon R. Finfer, Qiang Li, Colman Taylor, Jeremy Cohen, Yaseen Arabi, Rinaldo Bellomo, Laurent Billot, Meg Harward, Chris Joyce, Colin McArthur, John Myburgh, Anders Perner, Dorrilyn Rajbhandari, Andrew Rhodes, Kelly Thompson, Steve Webb, Balasubramanian Venkatesh

Internal Medicine

Research output: Contribution to journal › Article › peer-review

12 Citations (Web of Science)

Abstract

Purpose: To investigate the impact of hydrocortisone treatment and illness severity on health-related quality of life (HRQoL) at 6 months in septic shock survivors from the ADRENAL trial. Methods: Using the EuroQol questionnaire (EQ-5D-5L) at 6 months after randomization we assessed HRQoL in patient subgroups defined by hydrocortisone or placebo treatment, gender, illness severity (APACHE II < or ≥ 25), and severity of shock (baseline peak catecholamine doses < or ≥ 15 mcg/min). Additionally, in subgroups defined by post-randomisation variables; time to shock reversal (days), treatment with renal replacement therapy (RRT), and presence of bacteremia. Results: At 6 months, there were 2521 survivors. Of these 2151 patients (85.3%-1080 hydrocortisone and 1071 placebo) completed 6-month follow-up. Overall, at 6 months the mean EQ-5D-5L visual analogue scale (VAS) was 70.8, mean utility score 59.4. Between 15% and 30% of patients reported moderate to severe problems in any given HRQoL domain. There were no differences in any EQ-5D-5L domain in patients who received hydrocortisone vs. placebo, nor in the mean VAS (p = 0.6161), or mean utility score (p = 0.7611). In all patients combined, males experienced lower pain levels compared to females [p = 0.0002). Neither higher severity of illness or shock impacted reported HRQoL. In post-randomisation subgroups, longer time to shock reversal was associated with increased problems with mobility (p = < 0.0001]; self-care (p = 0.0.0142), usual activities (p = <0.0001] and pain (p = 0.0384). Amongst those treated with RRT, more patients reported increased problems with mobility (p = 0.0307) and usual activities (p = 0.0048) compared to those not treated. Bacteraemia was not associated with worse HRQoL in any domains of the EQ-5D-5L. Conclusions: Approximately one fifth of septic shock survivors report moderate to extreme problems in HRQoL domains at 6 months. Hydrocortisone treatment for septic shock was not associated with improved HRQoL at 6 months. Female gender was associated with worse pain at 6 months.

Original language	English
Pages (from-to)	1696-1706
Number of pages	11
Journal	Intensive Care Medicine
Volume	46
Issue number	9
DOIs	https://doi.org/10.1007/s00134-020-06169-1
Publication status	Published - 1 Sep 2020

Access to Document

10.1007/s00134-020-06169-1

Cite this

the ADRENAL Trial Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Hammond, N., Finfer, S. R., Li, Q., Taylor, C., Cohen, J., Arabi, Y., Bellomo, R., Billot, L., Harward, M., Joyce, C., McArthur, C., Myburgh, J., Perner, A., Rajbhandari, D., Rhodes, A., Thompson, K., Webb, S., & Venkatesh, B. (2020). Health-related quality of life in survivors of septic shock: 6-month follow-up from the ADRENAL trial. Intensive Care Medicine, 46(9), 1696-1706. https://doi.org/10.1007/s00134-020-06169-1

@article{58b330311b1b411fa162760a2c1edc73,

title = "Health-related quality of life in survivors of septic shock: 6-month follow-up from the ADRENAL trial",

abstract = "Purpose: To investigate the impact of hydrocortisone treatment and illness severity on health-related quality of life (HRQoL) at 6 months in septic shock survivors from the ADRENAL trial. Methods: Using the EuroQol questionnaire (EQ-5D-5L) at 6 months after randomization we assessed HRQoL in patient subgroups defined by hydrocortisone or placebo treatment, gender, illness severity (APACHE II < or ≥ 25), and severity of shock (baseline peak catecholamine doses < or ≥ 15 mcg/min). Additionally, in subgroups defined by post-randomisation variables; time to shock reversal (days), treatment with renal replacement therapy (RRT), and presence of bacteremia. Results: At 6 months, there were 2521 survivors. Of these 2151 patients (85.3%-1080 hydrocortisone and 1071 placebo) completed 6-month follow-up. Overall, at 6 months the mean EQ-5D-5L visual analogue scale (VAS) was 70.8, mean utility score 59.4. Between 15% and 30% of patients reported moderate to severe problems in any given HRQoL domain. There were no differences in any EQ-5D-5L domain in patients who received hydrocortisone vs. placebo, nor in the mean VAS (p = 0.6161), or mean utility score (p = 0.7611). In all patients combined, males experienced lower pain levels compared to females [p = 0.0002). Neither higher severity of illness or shock impacted reported HRQoL. In post-randomisation subgroups, longer time to shock reversal was associated with increased problems with mobility (p = < 0.0001]; self-care (p = 0.0.0142), usual activities (p = <0.0001] and pain (p = 0.0384). Amongst those treated with RRT, more patients reported increased problems with mobility (p = 0.0307) and usual activities (p = 0.0048) compared to those not treated. Bacteraemia was not associated with worse HRQoL in any domains of the EQ-5D-5L. Conclusions: Approximately one fifth of septic shock survivors report moderate to extreme problems in HRQoL domains at 6 months. Hydrocortisone treatment for septic shock was not associated with improved HRQoL at 6 months. Female gender was associated with worse pain at 6 months.",

keywords = "EQ5D, Health-related quality of life, Intensive care, Sepsis, Septic shock, Steroids",

author = "{the ADRENAL Trial Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group} and Naomi Hammond and Finfer, {Simon R.} and Qiang Li and Colman Taylor and Jeremy Cohen and Yaseen Arabi and Rinaldo Bellomo and Laurent Billot and Meg Harward and Chris Joyce and Colin McArthur and John Myburgh and Anders Perner and Dorrilyn Rajbhandari and Andrew Rhodes and Kelly Thompson and Steve Webb and Balasubramanian Venkatesh and Cowdrey, {Keri Anne} and Eileen Gilder and Stephanie Long and Lianne McCarthy and Shay McGuinness and Rachael Parke and Kristen Benefield and Yan Chen and Rachael McConnochie and Lynette Newby and Glenn Eastwood and Daryl Jones and Leah Peck and Helen Young and Catherine Boschert and John Edington and Jason Fletcher and Julie Smith and Dhaval Ghelani and Kiran Nand and Graham Reece and Treena Sara and Jeremy Bewley and Libby Cole and Lisa Grimmer and Lucy Howie and Shanaz James and Marta Kozlowski and Victoria Phillips and Sanjoy Shah and Katie Sweet and Denise Webster and Irene Bailey and Katrina Ellem and Toni McKenna and Seton Henderson and David Knight and Jan Mehrtens and Emmeline Minto and Sascha Noble and Zia Ansari and Samantha Bates and Craig French and Dashiell Gantner and Koottayi, {Sathyajith Velandy} and Forbes McGain and John Mulder and Anna Tippett and Miriam Towns and Christine Boyd and Verity Calder and Kayla Harris and Carmen Scott and Stephen Wright and {De Keulenaer}, Bart and Edward Litton and Annamaria Palermo and Adrian Regli and Alison Bone and Claire Cattigan and Tania Elderkin and Melissa Fraser and Chonghaile, {Martina Ni} and Neil Orford and Tania Salerno and Maimoonbe Gough and Jody Paxton and Mandy Tallott and James Winearls and Michael Bastick and Robert Cameron and Katrina Ellis and Atul Gaur and Rebecca Gregory and Jessica Naumoff and Mary White and Neeraj Bhadange and Nandan Bhende and Umakant Bhutada and Anand Krishnan and Rebecca Nunn and Judith Ochola and Kristine Ryan and Tracey Sandford and Shannon Treay and Miranda Hardie and Peter Harrigan and Rachael Paton and Emma Pollock and Rachael Whyte and Ehnidi, {Fatimah Al} and Enizi, {Farhan Al} and Qasim, {Eman Al} and Qahtani, {Moudi Al} and Saeedi, {Alawi Al} and Solamy, {Sami Al} and Shmylan Alharbi and Maamoun Dbsawy and Samir Hadad and Mohammed Muhaidib and Shihab Mundekkadan and Muath Najjar and Vusala Rzayeva and Musharaf Sadat and Sadaf Saedar and Husain Abdulmutalib and AlMaani, {Mohammed A.} and AlQurashi, {Alaa Ashraf B.} and Hani Lababidi and Ntinika, {and Pendo} and Ahmed Abdulmomen and Mariam Al-Ansari and Mohammad Hussein and Alexander Chan and Clair Harris and Phillip Hopkins and Lucy Johnson and Clare Mellis and Leah Thompson and Julia Wendon and Richard Breeze and Michaela Heller and Mick Jennings and Waqas Khaliq and Ingrid Krupe and Ashraf Molokhia and Mathin Mostert and Rosie Reece-Anthony and Rose, {Bernd Oliver} and Anders Aneman and Bradshaw, {Kerrie Ann} and Lien Lombardo and Claudia Lopez and Sharon Micallef and William O{\textquoteright}Regan and Antony Stewart and Lynette Morrison and Kellie Sosnowski and Joanne Sutton and Hayden White and Natalie Soar and Peter Thomas and Josette Wood and Jacqueline Atkins and Stuart Baker and Melissa Finney and Kye Gregory and Amod Karnik and Megan Martin and John Morgan and Maria Pietsch and Jeffrey Presneill and David Sturgess and Melissa Finney and Kye Gregory and Amod Karnik and Megan Martin and David Sturgess and Jefferson Aguila and Bernadette Clatworthy and Anisha Dias and Chantal Hogan and Alex Kazemi and Emmanuel Pelayo and Laura Rust and Rima Song and Anna Tilsley and Tony Williams and Hesham Abdelrahman and Lauren Bulfin and Tim Crozier and Darcy Davey and Jonathan Devine and Dhiraj Dwwivedi and Suzanne Eliott and David Ernest and Michelle Fernando and Kelli Fenech and Pauline Galt and Maja Green and Tammy Lamac and Klaudija Lavrans and Oakleigh Mullan and Paul Ritchie and Stephen Thornhill and Craig Walker and Huichun Wang and Stuart Wilson and Naomi Yarwood and Jane Brailsford and Anne Buckley and Loretta Forbes and Peter Garrett and John Moore and Lauren Murray and Rebecca Gresham and Julie Lowrey and Kristy Masters and Ian Seppelt and Fiona Symonds and Leonie Weisbrodt and Christina Whitehead and Jeanette Bell and Sheila Caniba and Maud Carpenter and Danielle Hacking and Janet Liang and Thomas, {and Caroline} and Olga Burgess and Angaj Ghosh and John Green and Vanessa Leonard-Roberts and Mary Park and Simone Said and Amanda Corley and Paul Jarrett and Michelle Campbell and Emma Reeves and Alex Poole and Paul Jarrett and Jane Thomas and Naomi Hammond and James Wun and John Smith and Samantha Smith and Roger Smith and Claire Reynolds and Judy Smith and Rebecca Cusack and Anna Hunt and Paul Young and Michael Davis",

year = "2020",

month = sep,

day = "1",

doi = "10.1007/s00134-020-06169-1",

language = "English",

volume = "46",

pages = "1696--1706",

journal = "Intensive Care Medicine",

issn = "0342-4642",

publisher = "Springer-Verlag London Ltd.",

number = "9",

}

the ADRENAL Trial Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Hammond, N, Finfer, SR, Li, Q, Taylor, C, Cohen, J, Arabi, Y, Bellomo, R, Billot, L, Harward, M, Joyce, C, McArthur, C, Myburgh, J, Perner, A, Rajbhandari, D, Rhodes, A, Thompson, K, Webb, S & Venkatesh, B 2020, 'Health-related quality of life in survivors of septic shock: 6-month follow-up from the ADRENAL trial', Intensive Care Medicine, vol. 46, no. 9, pp. 1696-1706. https://doi.org/10.1007/s00134-020-06169-1

Health-related quality of life in survivors of septic shock : 6-month follow-up from the ADRENAL trial. / the ADRENAL Trial Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group; Hammond, Naomi; Finfer, Simon R. et al.

In: Intensive Care Medicine, Vol. 46, No. 9, 01.09.2020, p. 1696-1706.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Health-related quality of life in survivors of septic shock

T2 - 6-month follow-up from the ADRENAL trial

AU - the ADRENAL Trial Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group

AU - Hammond, Naomi

AU - Finfer, Simon R.

AU - Li, Qiang

AU - Taylor, Colman

AU - Cohen, Jeremy

AU - Arabi, Yaseen

AU - Bellomo, Rinaldo

AU - Billot, Laurent

AU - Harward, Meg

AU - Joyce, Chris

AU - McArthur, Colin

AU - Myburgh, John

AU - Perner, Anders

AU - Rajbhandari, Dorrilyn

AU - Rhodes, Andrew

AU - Thompson, Kelly

AU - Webb, Steve

AU - Venkatesh, Balasubramanian

AU - Cowdrey, Keri Anne

AU - Gilder, Eileen

AU - Long, Stephanie

AU - McCarthy, Lianne

AU - McGuinness, Shay

AU - Parke, Rachael

AU - Benefield, Kristen

AU - Chen, Yan

AU - McConnochie, Rachael

AU - Newby, Lynette

AU - Eastwood, Glenn

AU - Jones, Daryl

AU - Peck, Leah

AU - Young, Helen

AU - Boschert, Catherine

AU - Edington, John

AU - Fletcher, Jason

AU - Smith, Julie

AU - Ghelani, Dhaval

AU - Nand, Kiran

AU - Reece, Graham

AU - Sara, Treena

AU - Bewley, Jeremy

AU - Cole, Libby

AU - Grimmer, Lisa

AU - Howie, Lucy

AU - James, Shanaz

AU - Kozlowski, Marta

AU - Phillips, Victoria

AU - Shah, Sanjoy

AU - Sweet, Katie

AU - Webster, Denise

AU - Bailey, Irene

AU - Ellem, Katrina

AU - McKenna, Toni

AU - Henderson, Seton

AU - Knight, David

AU - Mehrtens, Jan

AU - Minto, Emmeline

AU - Noble, Sascha

AU - Ansari, Zia

AU - Bates, Samantha

AU - French, Craig

AU - Gantner, Dashiell

AU - Koottayi, Sathyajith Velandy

AU - McGain, Forbes

AU - Mulder, John

AU - Tippett, Anna

AU - Towns, Miriam

AU - Boyd, Christine

AU - Calder, Verity

AU - Harris, Kayla

AU - Scott, Carmen

AU - Wright, Stephen

AU - De Keulenaer, Bart

AU - Litton, Edward

AU - Palermo, Annamaria

AU - Regli, Adrian

AU - Bone, Alison

AU - Cattigan, Claire

AU - Elderkin, Tania

AU - Fraser, Melissa

AU - Chonghaile, Martina Ni

AU - Orford, Neil

AU - Salerno, Tania

AU - Gough, Maimoonbe

AU - Paxton, Jody

AU - Tallott, Mandy

AU - Winearls, James

AU - Bastick, Michael

AU - Cameron, Robert

AU - Ellis, Katrina

AU - Gaur, Atul

AU - Gregory, Rebecca

AU - Naumoff, Jessica

AU - White, Mary

AU - Bhadange, Neeraj

AU - Bhende, Nandan

AU - Bhutada, Umakant

AU - Krishnan, Anand

AU - Nunn, Rebecca

AU - Ochola, Judith

AU - Ryan, Kristine

AU - Sandford, Tracey

AU - Treay, Shannon

AU - Hardie, Miranda

AU - Harrigan, Peter

AU - Paton, Rachael

AU - Pollock, Emma

AU - Whyte, Rachael

AU - Ehnidi, Fatimah Al

AU - Enizi, Farhan Al

AU - Qasim, Eman Al

AU - Qahtani, Moudi Al

AU - Saeedi, Alawi Al

AU - Solamy, Sami Al

AU - Alharbi, Shmylan

AU - Dbsawy, Maamoun

AU - Hadad, Samir

AU - Muhaidib, Mohammed

AU - Mundekkadan, Shihab

AU - Najjar, Muath

AU - Rzayeva, Vusala

AU - Sadat, Musharaf

AU - Saedar, Sadaf

AU - Abdulmutalib, Husain

AU - AlMaani, Mohammed A.

AU - AlQurashi, Alaa Ashraf B.

AU - Lababidi, Hani

AU - Ntinika, and Pendo

AU - Abdulmomen, Ahmed

AU - Al-Ansari, Mariam

AU - Hussein, Mohammad

AU - Chan, Alexander

AU - Harris, Clair

AU - Hopkins, Phillip

AU - Johnson, Lucy

AU - Mellis, Clare

AU - Thompson, Leah

AU - Wendon, Julia

AU - Breeze, Richard

AU - Heller, Michaela

AU - Jennings, Mick

AU - Khaliq, Waqas

AU - Krupe, Ingrid

AU - Molokhia, Ashraf

AU - Mostert, Mathin

AU - Reece-Anthony, Rosie

AU - Rose, Bernd Oliver

AU - Aneman, Anders

AU - Bradshaw, Kerrie Ann

AU - Lombardo, Lien

AU - Lopez, Claudia

AU - Micallef, Sharon

AU - O’Regan, William

AU - Stewart, Antony

AU - Morrison, Lynette

AU - Sosnowski, Kellie

AU - Sutton, Joanne

AU - White, Hayden

AU - Soar, Natalie

AU - Thomas, Peter

AU - Wood, Josette

AU - Atkins, Jacqueline

AU - Baker, Stuart

AU - Finney, Melissa

AU - Gregory, Kye

AU - Karnik, Amod

AU - Martin, Megan

AU - Morgan, John

AU - Pietsch, Maria

AU - Presneill, Jeffrey

AU - Sturgess, David

AU - Finney, Melissa

AU - Gregory, Kye

AU - Karnik, Amod

AU - Martin, Megan

AU - Sturgess, David

AU - Aguila, Jefferson

AU - Clatworthy, Bernadette

AU - Dias, Anisha

AU - Hogan, Chantal

AU - Kazemi, Alex

AU - Pelayo, Emmanuel

AU - Rust, Laura

AU - Song, Rima

AU - Tilsley, Anna

AU - Williams, Tony

AU - Abdelrahman, Hesham

AU - Bulfin, Lauren

AU - Crozier, Tim

AU - Davey, Darcy

AU - Devine, Jonathan

AU - Dwwivedi, Dhiraj

AU - Eliott, Suzanne

AU - Ernest, David

AU - Fernando, Michelle

AU - Fenech, Kelli

AU - Galt, Pauline

AU - Green, Maja

AU - Lamac, Tammy

AU - Lavrans, Klaudija

AU - Mullan, Oakleigh

AU - Ritchie, Paul

AU - Thornhill, Stephen

AU - Walker, Craig

AU - Wang, Huichun

AU - Wilson, Stuart

AU - Yarwood, Naomi

AU - Brailsford, Jane

AU - Buckley, Anne

AU - Forbes, Loretta

AU - Garrett, Peter

AU - Moore, John

AU - Murray, Lauren

AU - Gresham, Rebecca

AU - Lowrey, Julie

AU - Masters, Kristy

AU - Seppelt, Ian

AU - Symonds, Fiona

AU - Weisbrodt, Leonie

AU - Whitehead, Christina

AU - Bell, Jeanette

AU - Caniba, Sheila

AU - Carpenter, Maud

AU - Hacking, Danielle

AU - Liang, Janet

AU - Thomas, and Caroline

AU - Burgess, Olga

AU - Ghosh, Angaj

AU - Green, John

AU - Leonard-Roberts, Vanessa

AU - Park, Mary

AU - Said, Simone

AU - Corley, Amanda

AU - Jarrett, Paul

AU - Campbell, Michelle

AU - Reeves, Emma

AU - Poole, Alex

AU - Jarrett, Paul

AU - Thomas, Jane

AU - Hammond, Naomi

AU - Wun, James

AU - Smith, John

AU - Smith, Samantha

AU - Smith, Roger

AU - Reynolds, Claire

AU - Smith, Judy

AU - Cusack, Rebecca

AU - Hunt, Anna

AU - Young, Paul

AU - Davis, Michael

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Purpose: To investigate the impact of hydrocortisone treatment and illness severity on health-related quality of life (HRQoL) at 6 months in septic shock survivors from the ADRENAL trial. Methods: Using the EuroQol questionnaire (EQ-5D-5L) at 6 months after randomization we assessed HRQoL in patient subgroups defined by hydrocortisone or placebo treatment, gender, illness severity (APACHE II < or ≥ 25), and severity of shock (baseline peak catecholamine doses < or ≥ 15 mcg/min). Additionally, in subgroups defined by post-randomisation variables; time to shock reversal (days), treatment with renal replacement therapy (RRT), and presence of bacteremia. Results: At 6 months, there were 2521 survivors. Of these 2151 patients (85.3%-1080 hydrocortisone and 1071 placebo) completed 6-month follow-up. Overall, at 6 months the mean EQ-5D-5L visual analogue scale (VAS) was 70.8, mean utility score 59.4. Between 15% and 30% of patients reported moderate to severe problems in any given HRQoL domain. There were no differences in any EQ-5D-5L domain in patients who received hydrocortisone vs. placebo, nor in the mean VAS (p = 0.6161), or mean utility score (p = 0.7611). In all patients combined, males experienced lower pain levels compared to females [p = 0.0002). Neither higher severity of illness or shock impacted reported HRQoL. In post-randomisation subgroups, longer time to shock reversal was associated with increased problems with mobility (p = < 0.0001]; self-care (p = 0.0.0142), usual activities (p = <0.0001] and pain (p = 0.0384). Amongst those treated with RRT, more patients reported increased problems with mobility (p = 0.0307) and usual activities (p = 0.0048) compared to those not treated. Bacteraemia was not associated with worse HRQoL in any domains of the EQ-5D-5L. Conclusions: Approximately one fifth of septic shock survivors report moderate to extreme problems in HRQoL domains at 6 months. Hydrocortisone treatment for septic shock was not associated with improved HRQoL at 6 months. Female gender was associated with worse pain at 6 months.

AB - Purpose: To investigate the impact of hydrocortisone treatment and illness severity on health-related quality of life (HRQoL) at 6 months in septic shock survivors from the ADRENAL trial. Methods: Using the EuroQol questionnaire (EQ-5D-5L) at 6 months after randomization we assessed HRQoL in patient subgroups defined by hydrocortisone or placebo treatment, gender, illness severity (APACHE II < or ≥ 25), and severity of shock (baseline peak catecholamine doses < or ≥ 15 mcg/min). Additionally, in subgroups defined by post-randomisation variables; time to shock reversal (days), treatment with renal replacement therapy (RRT), and presence of bacteremia. Results: At 6 months, there were 2521 survivors. Of these 2151 patients (85.3%-1080 hydrocortisone and 1071 placebo) completed 6-month follow-up. Overall, at 6 months the mean EQ-5D-5L visual analogue scale (VAS) was 70.8, mean utility score 59.4. Between 15% and 30% of patients reported moderate to severe problems in any given HRQoL domain. There were no differences in any EQ-5D-5L domain in patients who received hydrocortisone vs. placebo, nor in the mean VAS (p = 0.6161), or mean utility score (p = 0.7611). In all patients combined, males experienced lower pain levels compared to females [p = 0.0002). Neither higher severity of illness or shock impacted reported HRQoL. In post-randomisation subgroups, longer time to shock reversal was associated with increased problems with mobility (p = < 0.0001]; self-care (p = 0.0.0142), usual activities (p = <0.0001] and pain (p = 0.0384). Amongst those treated with RRT, more patients reported increased problems with mobility (p = 0.0307) and usual activities (p = 0.0048) compared to those not treated. Bacteraemia was not associated with worse HRQoL in any domains of the EQ-5D-5L. Conclusions: Approximately one fifth of septic shock survivors report moderate to extreme problems in HRQoL domains at 6 months. Hydrocortisone treatment for septic shock was not associated with improved HRQoL at 6 months. Female gender was associated with worse pain at 6 months.

KW - EQ5D

KW - Health-related quality of life

KW - Intensive care

KW - Sepsis

KW - Septic shock

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=85090509268&partnerID=8YFLogxK

U2 - 10.1007/s00134-020-06169-1

DO - 10.1007/s00134-020-06169-1

M3 - Article

C2 - 32676679

AN - SCOPUS:85090509268

VL - 46

SP - 1696

EP - 1706

JO - Intensive Care Medicine

JF - Intensive Care Medicine

SN - 0342-4642

IS - 9

ER -

Health-related quality of life in survivors of septic shock: 6-month follow-up from the ADRENAL trial

Abstract

Access to Document

Other files and links

Fingerprint

Cite this